Evidence map›Paper›PMID 38534644›Full record

ArticleAntibiotics (Basel, Switzerland)2024

A FtsZ Inhibitor That Can Utilize Siderophore-Ferric Iron Uptake Transporter Systems for Activity against Gram-Negative Bacterial Pathogens.

Eric J Bryan, Qi Qiao, Yuxuan Wang, Jacques Y Roberge, Edmond J LaVoie, Daniel S Pilch

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Eric J BryanDepartment of Pharmacology, Rutgers Robert Wood Johnson Medical School, Piscataway, NJ 08854, USA.
Qi QiaoDepartment of Molecular Design and Synthesis, Rutgers University Biomedical Innovation Cores, Piscataway, NJ 08854, USA.
Yuxuan WangDepartment of Pharmacology, Rutgers Robert Wood Johnson Medical School, Piscataway, NJ 08854, USA.ORCID 0000-0003-0771-1078
Jacques Y RobergeDepartment of Molecular Design and Synthesis, Rutgers University Biomedical Innovation Cores, Piscataway, NJ 08854, USA.ORCID 0000-0002-7810-4139
Edmond J LaVoieDepartment of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA.ORCID 0000-0001-9244-1249
Daniel S PilchDepartment of Pharmacology, Rutgers Robert Wood Johnson Medical School, Piscataway, NJ 08854, USA.ORCID 0000-0002-0113-0849
Rutgers, The State University of New Jersey · US

Funding

New Jersey Health Foundation PC154-23Rutgers, The State University of New Jersey Busch Biomedical Grant
6 · The paper itself

Abstract

The global threat of multidrug-resistant Gram-negative bacterial pathogens necessitates the development of new and effective antibiotics. FtsZ is an essential and highly conserved cytoskeletal protein that is an appealing antibacterial target for new antimicrobial therapeutics. However, the effectiveness of FtsZ inhibitors against Gram-negative species has been limited due in part to poor intracellular accumulation. To address this limitation, we have designed a FtsZ inhibitor (

Indexed as

Acinetobacter baumanniiantibiotic-siderophore conjugateantibiotic uptakeFtsZ inhibitor-antibiotic synergyKlebsiella pneumoniae

Identifiers

PMID38534644
PMCPMC10967458
OpenAlexW4392038911

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.